Giasson Benoit I, Van Deerlin Vivianna M
Department of Pharmacology, University of Pennsylvania, Philadelphia, PA 19104-6084, USA.
Neurosignals. 2008;16(1):99-105. doi: 10.1159/000109764. Epub 2007 Dec 5.
Mutations in leucine-rich repeat kinase 2 (LRRK2) are the most common known cause of late-onset Parkinson's disease (PD). Clinical and pathological studies have demonstrated that in the majority of cases LRRK2 mutations lead to PD with classical clinical and pathological features. However, in some patients the pathological features can be distinct and/or more extensive than typically seen in PD. Collectively, these findings provide important clues into the mechanisms by which LRRK2 mutations can lead to demise of dopaminergic neurons. The understanding of LRRK2 protein function and its gene regulation and the consequences of mutations are still at their infancy, but scientific findings are progressing at a rapid pace. Although more detailed information on LRRK2 is still needed in the quest for therapeutic intervention that could halt or slow the progression of disease, here we summarize the current information on the biological and pathological properties of LRRK2.
富含亮氨酸重复激酶2(LRRK2)突变是已知的晚发型帕金森病(PD)最常见病因。临床和病理研究表明,在大多数情况下,LRRK2突变导致具有典型临床和病理特征的帕金森病。然而,在一些患者中,其病理特征可能与典型帕金森病不同和/或更广泛。总体而言,这些发现为LRRK2突变导致多巴胺能神经元死亡的机制提供了重要线索。对LRRK2蛋白功能及其基因调控以及突变后果的理解仍处于起步阶段,但科学发现正迅速发展。尽管在寻求能够阻止或减缓疾病进展的治疗干预措施方面仍需要更多关于LRRK2的详细信息,但在此我们总结了关于LRRK2生物学和病理学特性的当前信息。